Lupus pain drug shows promise in early trial
NCT ID NCT03093402
First seen May 07, 2026 · Last updated Jun 19, 2026 · Updated 10 times
Summary
This phase 2 study tested whether JBT-101 (lenabasum) can reduce joint pain in people with systemic lupus erythematosus (SLE). 109 adults with active arthritis and at least moderate pain took either the drug or a placebo for 84 days. The main goal was to see if pain scores improved more with JBT-101 than with placebo.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for LUPUS are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Bronx-Lebanon Hospital Center: Division of Rheumatology
The Bronx, New York, 10457, United States
-
Columbia University Medical Center: Department of Medicine, Division of Rheumatology
New York, New York, 10032, United States
-
Duke University
Durham, North Carolina, 27710, United States
-
Emory University: Division of Rheumatology
Atlanta, Georgia, 30322, United States
-
Feinstein Institute for Medical Research: Center for Autoimmune and Musculoskeletal Diseases
Manhasset, New York, 11030, United States
-
Medical University of South Carolina
Charleston, South Carolina, 29425, United States
-
MetroHealth Medical Center
Cleveland, Ohio, 44109, United States
-
New York University Langone Medical Center: Department of Medicine, Division of Rheumatology
New York, New York, 10016, United States
-
Penn State MS Hershey Medical Center
Hershey, Pennsylvania, 17033, United States
-
Temple University
Philadelphia, Pennsylvania, 19140, United States
-
UCLA Medical Center: Division of Rheumatology
Los Angeles, California, 90095, United States
-
University of California San Diego School of Medicine: Division of Rheumatology, Allergy and Immunology
La Jolla, California, 92093, United States
-
University of California San Francisco School of Medicine: Lupus Clinic and Rheumatology Clinical Research Center
San Francisco, California, 94143, United States
-
University of Pennsylvania
Philadelphia, Pennsylvania, 19104, United States
-
University of Pittsburgh Medical Center: Division of Rheumatology and Clinical Immunology
Pittsburgh, Pennsylvania, 15217, United States
-
Yale University
New Haven, Connecticut, 06520, United States
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
JBT-101 (lenabasum)
What this could lead to
If it works, this could point toward a new way to ease lupus joint pain without suppressing the immune system.
What could go wrong
This is a small, early-phase trial (109 people) testing pain relief, not a cure. The drug may not prove better than placebo, and side effects are still being studied.
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.